ZYMEWORKS INC. Cash and Restricted Cash
ZYMEWORKS INC. (ZYME) had Cash and Restricted Cash of $179.41 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $179.41M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $244.28M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.16M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $64.83M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $179.41M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $244.28M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $41.16M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $64.83M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $98.25M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $76.20M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $66.10M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $122.36M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $70.96M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $114.81M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $157.56M 10-K · filed 2026-03-02 |
| 2023-09-30 | $94.33M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $142.10M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $181.58M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $400.91M 10-K · filed 2026-03-02 |
| 2022-09-30 | $96.08M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $198.65M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $275.52M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $201.87M 10-K · filed 2025-03-05 |
| 2021-09-30 | $253.44M 10-Q · filed 2022-11-08 |
| 2020-12-31 | $242.04M 10-K · filed 2024-03-06 |
| 2019-12-31 | $128.45M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |